Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 136

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 136
---
2022 |        |   |
|:-----------------------------------------------------------------------|:----|:---------------------------|:-------|:--|:----|:-----|-------:|:--|:----|:----------------|:-------|:--|:----|:-----|-------:|:--|
|                                                                        |     | -£ in thousands; unaudited |        |   |     |      |        |   |     | -£ in thousands |        |   |     |      |        |   |
| Cash flows from operating activities before changes in working capital |     |                            | (3,935 | ) |     |      | (4,086 | ) |     |                 | (7,622 | ) |     |      | (8,246 | ) |
| Changes in working capital                                             |     |                            | (872   | ) |     |      |    205 |   |     |                 | (49    | ) |     |      |    520 |   |
| Cash used in operations                                                |     |                            | (4,807 | ) |     |      | (3,881 | ) |     |                 | (7,671 | ) |     |      | (7,726 | ) |

Cash flows from Operating Activities before Changes in Working Capital. Net cash outflow from operating activities before changes in working capital was £3.94
million in the first six months of 2024, as opposed to £4.09 million during the same period in 2023. The decreased cash outflow
of £0.15 million, or 4%, was driven by a decrease in losses attributable to the owners of the Company of £0.26 million, offset
by higher negative non-cash items.

Net cash outflow from operating activities before changes in working capital was £7.62 million in the year ended December 31, 2023, as opposed to £8.25 million during the same period in 2022.

| 69 |

This reduced cash outflow of £0.62 million was driven by lower losses attributable to the owners of the Company of £0.58 million and a lower tax credit of £0.43 million, offset by reduced share-based payment expenses of £0.10 million and an increase in net finance income of £0.08 million. Included in cash flows from operating activities in 2023 was £0.08 million in respect of the forgiveness of a loan to Adher